Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell January 23, 2024 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial December 09, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results November 07, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition November 02, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases November 01, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023 October 31, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA September 06, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results August 08, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023 August 01, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818) July 06, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference June 29, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference May 31, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma May 17, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results May 08, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023 April 20, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting April 17, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma April 03, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results March 28, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023 March 21, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting March 14, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal February 21, 2023 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition December 12, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022 December 05, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology November 14, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results November 03, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition November 03, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022 October 27, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer October 25, 2022 From Corvus Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRVS Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
